Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8+ T cells to enhance antitumor immunity
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-10
DOI
10.1007/s00262-020-02722-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses
- (2018) Jai S. Rudra et al. VACCINE
- Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
- (2018) Abigail E. Overacre-Delgoffe et al. Cancer Immunology Research
- IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells
- (2018) Natasha C. Ward et al. JOURNAL OF IMMUNOLOGY
- Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2—A Balancing Act
- (2018) Vandana Kalia et al. Frontiers in Immunology
- Trial Watch: Toll-like receptor agonists in cancer immunotherapy
- (2018) Melody Smith et al. OncoImmunology
- Regulatory T cells in cancer immunotherapy
- (2016) Atsushi Tanaka et al. CELL RESEARCH
- NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models
- (2016) D. H. Charych et al. CLINICAL CANCER RESEARCH
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- TLR4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A Differentially Regulate Effector and Memory CD8+ T Cell Differentiation
- (2014) W. Cui et al. JOURNAL OF IMMUNOLOGY
- The Role of Protein Modifications of T-Bet in Cytokine Production and Differentiation of T Helper Cells
- (2014) Sera Oh et al. Journal of Immunology Research
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2
- (2013) T. Carmenate et al. JOURNAL OF IMMUNOLOGY
- Transient Enhanced IL-2R Signaling Early during Priming Rapidly Amplifies Development of Functional CD8 + T Effector-Memory Cells
- (2012) Iris Castro et al. JOURNAL OF IMMUNOLOGY
- Prolonged Interleukin-2Rα Expression on Virus-Specific CD8+ T Cells Favors Terminal-Effector Differentiation In Vivo
- (2010) Vandana Kalia et al. IMMUNITY
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for Autoimmunity
- (2009) J. B. Jacob et al. JOURNAL OF IMMUNOLOGY
- The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin synthesis
- (2009) R. P. McGlinchey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Blimp-1 directly repressesIl2and theIl2activatorFos, attenuating T cell proliferation and survival
- (2008) Gislâine A. Martins et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now